Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 5Thyroid Carcinoma, Anaplastic 4Neuroendocrine Tumors 4Thyroid Cancer, Papillary 3Carcinoma, Medullary 3Adenocarcinoma, Follicular 2Wilms Tumor 1Vipoma 1Thyroid cancer, medullary 1Thyroid cancer, Hurthle cell 1Thyroid Diseases 1Somatostatinoma 1Neoplastic Cells, Circulating 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Insulinoma 1Glucagonoma 1Gastrinoma 1Familial medullary thyroid carcinoma 1Differentiated Thyroid Cancer 1Carcinoma, Islet Cell 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Adrenocortical Carcinoma 1Adenoma, Islet Cell 1

Interventions

vandetanib 1sacubitril and valsartan sodium hydrate drug combination 1lenvatinib 1fluorodopa F 18 1cabozantinib 1Sorafenib 13-(3'-adamantan-1-yl-4'-methoxybiphenyl-4-yl)-2-propenoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid cancer, medullary × Sorafenib × Endocrine × Clear all
NCT03630120 2021-07-14

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
6 enrolled 9 charts
EndocrineHead & Neck

Thyroid cancer, medullary, Thyroid Cancer, Papillary, Thyroid Diseases, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡